There’s nothing wrong with this little company and their big drug. They are putting together lots of data relatively quickly in the inexpensive 1a and 1b trials that should convince those who need to be convinced. I think it’s a creatively smart strategy at this point. Not only is safety being reinforced, but efficacy will be further implied.